Ghrelin, a GH-releasing acylated peptide, has been recently identified from the rat stomach. The purified peptide consists of 28 amino acids in which the serine 3 residue is n-octanoylated. Here we show that ghrelin messenger RNA and ghrelin peptide are present in the human as well as in rat placentae. In human placenta, ghrelin was detected by PCR at both first trimester and after delivery. While ghrelin was not detected by immunohistochemistry in human placenta at term, it was easily identified by immunohistochemistry at first trimester being mainly expressed in cytotrophoblast cells and scarcely in syncytiotrophoblast ones. Ghrelin was also identified in a human choriocarcinoma cell line, the BeWo cells. Ghrelin was found, by immunohistochemistry, in the cytoplasm of labyrinth trophoblast of rat placenta, whereas other placental cell types seems to be negative for ghrelin immunostaining. Moreover, placental ghrelin messenger RNA, in pregnant rats, showed a characteristic profile of expression being practically undetectable during early pregnancy, with a sharp peak of expression at day 16 and decreasing in the latest stages of gestation. In conclusion, ghrelin has been detected in human and rat placenta showing a pregnancy-related time course of expression. Whether placenta-derived ghrelin is involved in the modulation of GH release, or placental cell growth and differentiation remains to be established. (Endocrinology 142: 788 -794, 2001 ) G H SECRETAGOGUES (GHSs) are artificial compounds that release GH in all species, including man. Up to now, these molecules mimicked an unknown endogenous factor that activates the GHS receptor in the pituitary and in the hypothalamus. The cloning of GHS-R (1, 2) suggested that an endogenous ligand for this receptor might exist; this was confirmed by the recent identification and purification of ghrelin by Kojima et al. (3). This novel GH-releasing peptide was isolated and characterized from rat stomach and amino acid sequence revealed 28 amino acidic residues. Detailed structural analysis of the peptide demonstrated that the serine in position 3 had an hydrophobic domain corresponding to an acylated residue (n-octanoyl) that confers the biological activity to the peptide. In vitro and in vivo assays revealed that ghrelin is able to induce GH release in a clear dose-dependent manner. More recently a second endogenous ligand for GH secretagogue receptor named des-
G H SECRETAGOGUES (GHSs) are artificial compounds
that release GH in all species, including man. Up to now, these molecules mimicked an unknown endogenous factor that activates the GHS receptor in the pituitary and in the hypothalamus. The cloning of GHS-R (1, 2) suggested that an endogenous ligand for this receptor might exist; this was confirmed by the recent identification and purification of ghrelin by Kojima et al. (3) . This novel GH-releasing peptide was isolated and characterized from rat stomach and amino acid sequence revealed 28 amino acidic residues. Detailed structural analysis of the peptide demonstrated that the serine in position 3 had an hydrophobic domain corresponding to an acylated residue (n-octanoyl) that confers the biological activity to the peptide. In vitro and in vivo assays revealed that ghrelin is able to induce GH release in a clear dose-dependent manner. More recently a second endogenous ligand for GH secretagogue receptor named des-Gln14-ghrelin whose sequence is identical to ghrelin except for one glutamine in position 14 has been purified and characterized (4) . This peptide is not encoded by a gene distinct from ghrelin but is encoded by a messenger RNA (mRNA) created by alternative splicing of the ghrelin gene.
On the other hand, the placenta is a short-lived organ able to express and release a variety of hormones and with a complex and badly understood regulation. Several members of the somatotrophic axis, such as GH, GHRH, IGF-1, somatostatin, and GH variants have been detected in placenta of both human and experimental animals. While some hormones are secreted in a statical form, i.e. without changes along pregnancy, others are time related. To verify if ghrelin tissue expression was present in a relevant endocrine tissue as placenta, the tissue distribution and pregnancy-related variations of ghrelin were assessed in both human and rat placenta.
Materials and Methods

Tissues explant and RNA preparation
Rat tissues were obtained from female Sprague Dawley rats at different stages of pregnancy. Placentae were carefully dissected removing fetus and other membranes, trying to minimize all possible contaminations from other tissues (i.e. decidua, miometrium etc.). For the analysis of 8 and 12 days placentae, only choriovitelline placental structures were used (this tissue at this stage of pregnancy is 1-3 mm large and it is quite easily differentiated from the adjacent tissues). First trimester human placenta was obtained from the Department of Morphological Science of the University of Santiago de Compostela. Human placenta at term (after delivery) was obtained from the service of Obstethrics and Ginecology of Complejo Hospitalario of Santiago. RNA was isolated from frozen or freshly explanted tissues by Trizol-LS 3 TM method as previously described (5) (Life Technologies, Inc., Grand Island, NY). Tissues (about 100 mg) were homogenized using a Polytron 3 homog-enizer in 1000 l of Trizol LS reagent and, recovery of total RNA after isopropanol precipitation, was measured with a spectrophotometer (Beckman Inc., Fullterton, CA; DU62) at 260 nm. The amplification profile for rat ghrelin was: denaturation at 98 C for 10 sec, annealing at 55 C for 30 sec, and extension at 72 C for 1 min while for human ghrelin was: denaturation at 98 C for 20 sec, annealing at 58 C for 30 sec, and extension at 72 C for 1 min. Thirty five-cycle amplification was completed with an additional step at 72 C for 10 min. The amplification was performed in an automatic thermal cycler (Mastercycler gradient-Eppendorf). To assure that PCR was performed in the linear amplification range, samples were taken after 15, 20, 25, 30, 35 , and 40 cycles, showing that the reaction was linear over this range (data not shown).
RT-PCR and Southern analysis
To check the quality of mRNA in each sample, rat ghrelin RNA was amplified together with ␤-actin. For ␤-actin, two specific primers span introns were used, which do not coamplify processed pseudogenes (6): forward primer (5Ј-TACAACTCCTTGCAGCTCC-3Ј) and reverse primer (5Ј-ATCTTCATGAGGTAGTCAGTC-3Ј). PCR generates a single 347-bp product for rat ghrelin and a single 603-bp product for the ␤-actin gene.
Human ghrelin RNA was amplified together with hHPRT: forward primer (5Ј-AGCAAGACGTTCAGTCCTGTC-3Ј) and reverse primer (5Ј-CAGCCCTGCCGTCGTGATTA-3Ј). PCR reaction generates a single 327-bp product for rat ghrelin and a single 139-bp product for the hHPRT.
Multiple positive and negative controls were performed for RT-PCR. Negative controls consisted of omitting the RT reaction for each sample or amplifying samples of RT reaction without MMLV. To exclude a competitive amplification of genomic DNA, we have performed RT-PCR on rat genomic DNA. All negative controls resulted in no bands after amplification. The identity of the amplimer for ghrelin was confirmed performing the RT-PCR together with positive controls (purified cloned cDNAs for rat and human ghrelin: free insert and whole plasmid encoding the peptide). PCR products were separated on 1.5% agarose gel, stained with ethidium bromide and examined with UV light and visualized with a Gel Doc 1000 Documentation System (Bio-Rad Laboratories, Inc., Hercules, CA). To confirm authenticity of the amplimers, Southern blot analysis was carried out. Hybridization of nylon transferred resolved amplicons was performed using a 32 P cDNA specific antisense probe for rat ghrelin. Hybridization was carried on at 44 C for 18 h. After removing the excess of labeled probe by washing, membranes were exposed to autoradiography, and the sizes of the bands determined by comparison with molecular weight marker on the ethidium bromide stained agarose gel pictures.
Northern blot analysis
For these studies, placentae and other tissues were dissected from female Sprague Dawley rats as above described and snap frozen on dry ice or immediately processed. RNA was extracted by a guanidium isothiocyanate-phenol method, and 25 g of total RNA were fractionated by agarose gel electrophoresis. The 28s and 18s RNA bands were visualized by ethidium bromide staining with a Gel Doc 1000 Documentation System (Little Chalfont, Buckinghamshire, UK).
RNA was transferred by capillary blotting onto a charged nylon membrane and fixed with UV light. The filter was hybridized to a 32 P-labeled cDNA probe (501 bp) to rat ghrelin. Rat ghrelin cDNA was purified from plasmid expression vector with Sephaglas BandPrep Kit (Amersham Pharmacia Biotech). The probe was prepared by random prime labeling the rat ghrelin cDNA subcloned in EcoRI double restriction site of a pBS-SK(Ϫ) expression vector. Hybridization was performed overnight at 42 C in prehybridization buffer contain the labeled probe (1 ϫ 10 6 cpm/ml), 6 post hybridization washes were performed before to expose the filter to x-ray film. Multiple exposure times, followed by densitometric analysis, were performed to ensure that the relative signals obtained indicated actual changes in mRNA levels and not merely artifacts due to any nonlinearity in film exposure. Relative mRNA levels obtained at different exposure times gave similar quantitative alterations. A rat 18S ribosomal RNA oligonucleotide probe 5Ј-ACGG-TATCTGATCGTCTTCGAACC-3Ј (Amersham Pharmacia Biotech) was used to assess the amount and integrity of total RNA loaded in each gel. The oligonucleotide was end-labeled with 32 P by polynucleotide kinase (Promega Corp.) and hybridized with filters in a buffer containing 10ϫ Denhardt's solution, 0.1% SDS, 2ϫ SSC, and 100 g/ml salmon sperm DNA at 50C for 24 h. The filters were then successively washed and processed as previously described.
Immunohistochemistry
Specimens of rat stomach and placenta were immersion fixed in 4% buffered formaldehyde for 24 h, dehydrated, and embedded in paraffin by standard procedure. Sections 5-m thick were mounted on silanized slices, dewaxed, rehydrated, and immunostained by the streptavidinbiotin peroxidase complex (SABC) procedure. The sections were consecutively incubated in the following: 1) Rabbit anti ghrelin polyclonal antibody, at a dilution of 1:500 in PBS (0.01 m phosphate buffer, pH 7.4, containing 0.15 m NaCl) with 0.1% BSA (Sigma, St Louis, MO), for 1 h at room temperature. 2) 3% hydrogen peroxide for 10 min. 3) Biotinylated goat antibody to rabbit immunoglobulins at 1:100 dilution in PBS with 2% normal goat serum (Duet kit, Dakopatts, Glostrup, Denmark) for 30 min. 4) Streptavidin-biotin-peroxidase complex (Duet kits, Dakopatts), prepared 30 min before use according to the protocol provided by manufacturer. 5) 3,3Ј-diamino-benzidinetetrahydrochloride (DAB) solution for 10 min. DAB solution was prepared by dissolving 1 DAB buffer tablet (Merck, Darmstadt, Germany) in 10 ml of distilled water. Between steps the sections were washed with PBS (2 ϫ 5 min) and after step 5 with distilled water. No counterstaining was done. Negative controls were performed by either 1) omitting any essential step of the reaction; 2) substituting the ghrelin antibody with appropriate dilution of normal (nonimmune) mouse serum (Dakopatts); and 3) preabsorbing the anti ghrelin antibody with the homologous antigen (ghrelin 10 nmol/ml) for 24 h at 4C.
Animal models
To verify ghrelin expression in rat in physiological models, ghrelin mRNA expression along pregnancy was analyzed by Northern blot analysis in placenta and in stomach. Female pregnant Sprague Dawley rats were euthanized at different times of pregnancy: 8, 12, 16, 19, and 21 days. Placentae and stomach were dissected as above described and snap frozen on dry ice. Samples were immediately used for Northern analysis or stored at Ϫ80 C until use. Stomach RNA from post coitus female rats was used as reference in the study performed on rat stomach.
Results
As shown in Fig. 1 , ghrelin mRNA was found in human postpartum normal placenta samples by using RT-PCR analysis. This result was also confirmed performing RT-PCR on human placentae at first trimester (data not shown). The identity of the amplimers was confirmed by restriction enzyme cleavage of the amplicons with SacI, which originated two products: one of 75-bp and another of 252 bp, positive control of restriction digestion was performed on the amplification product of the purified cloned human pre-pro ghrelin cDNA (data not shown). Interestingly, and as a complementary result, ghrelin was also detected in an human tumor cell line as coriocarcinoma BeWo cells (Fig. 1) , although this expression was quite lower than in normal human placenta.
Ghrelin peptide was heavily expressed in first trimester human placenta ( Fig. 2A) with a peculiar distribution pattern. In fact, ghrelin was mainly expressed in cytotrophoblast cells and to a lesser extent in syncytiotrophoblast cells. In human stomach, used as positive control (Fig. 2C) , ghrelin was found in the neuroendocrine cells of the fundic glands. Interestingly, ghrelin expression vanished with the evolution of pregnancy, and in full-term human placentae after delivery peptide levels were so low that immunostaining became negative (Fig. 2B) . To detect if these findings were species specific, we have performed RT-PCR analysis on rat samples. This analysis revealed the presence of ghrelin transcripts in 21 days pregnant rat placenta (Fig. 3) . The identity of the amplimers was confirmed by restriction enzyme cleavage of the PCR amplification products with ApaI, which originated two products: one of 138 bp and another of 209 bp. Positive control of restriction digestion was performed on the amplification product of the purified cloned rat pre-pro ghrelin cDNA, furnishing identical results (data not shown). To verify the authenticity of the amplicons, we have performed Southern analysis of PCR amplification products with a specific cDNA antisense probe for rat ghrelin. As shown in Fig.  3 , B and D, ghrelin was easily identified in rat placenta, as well as in other tissues in which ghrelin was previously described This result was unambiguously confirmed by Northern blot analysis of rat tissues, showing that a messenger RNA for ghrelin is present in the placenta. No detectable Northern blot signals, as well as RT-PCR amplified bands, were observed in the other screened tissues used for intend negative control (Figs. 3 and 4) . In the rat placenta, immunoreactivity for ghrelin was demonstrated in labyrinth trophoblast cells (Fig. 5, A and B, middle and right) , whereas the spongiotrophoblast and secondary giant trophoblasts of the junctional layer were negative (Fig. 5A, left) . In the gastric sections, used as positive control, immunoreactivity for ghrelin was strongly observed (Fig. 5C ) in the cytoplasm of neuroendocrine cells primarily situated at the base of fundic glands.
To detect if placental ghrelin was related with the evolution of pregnancy, a time-course study was undertaken. As shown in Fig. 6 (upper panel) , a pattern of expression coincident with that found in human placenta was observed in rat placenta. No detectable signals for ghrelin were observed in placenta at day 8 and 12 of pregnancy afterwards, a clear increase of expression was observed at day 16 while at days 19 and 21 ghrelin expression decreases up to lower levels. On the contrary, no differences were observed in ghrelin mRNA expression in rat stomach. The densitometric analysis of the bands, normalized by OD in arbitrary units of 18S RNA, is reported in Fig. 7 . Moreover, Northern analysis of 16 days pregnant uteri did not show any signal, as well as nonpregnant uteri. However, a clear band was observed in 16 days placenta, as previously observed, confirming that the result obtained is due only to placental ghrelin RNA and not to decidual and/or other placental membranes contamination (Fig. 4C) . In addition, immunohistochemistry of 8 days pregnant uterus did not show any immunoreactive signal for ghrelin (Fig. 8) .
Discussion
In the present work, and to the best of our knowledge, for the first time it has been unambiguously identified the expression of ghrelin in the human and rat placenta. The identification has been accomplished by several different immunological and molecular approaches as RT-PCR, Northern and Southern blot analysis, and immunohistochemistry. Ghrelin seems to be specifically related to some functions, and its expression was confined to only peculiar cells of the organ. In fact, cytotrophoblast cells in human and labyrinth trophoblast cells in rat showed the highest peptide expression, while other cell types such as syncytiotrophoblast cells showed lower expression. In human placenta, ghrelin appears to be mainly expressed in the first half of pregnancy, whereas it could not be detected at term. In the rat placenta, expression increases along pregnancy and appears to be present at the later stages of pregnancy, day 16, and still a quite large degree of expression appears to be present at term.
These results are suggesting that, with advanced differentiation of placental tissues, ghrelin vanishes. However, one of the most significant findings was the time of pregnancyrelated changes in ghrelin expression observed in rat samples. These observations powerfully suggest that ghrelin is not just a marker of placental tissue, but that it undertakes a physiological role in placental function. Whether this role consists in placental regulation of peripheral functions or if it is needed for placental development is not possible to ascertain at present.
It is not possible to ascertain at present the role of placenta- derived ghrelin in either the pregnancy period or in the fetal physiology. One of the peculiar features of placental endocrinology is that in some instances it mimics the function of other endocrine glands. Interestingly, all the main regulatory components of the somatotrophic axis appear to be present in the placenta (7) (8) (9) (10) . Available evidences demonstrate the presence of GH regulatory hormones that are prevalently hypothalamic. For instance, immunoreactive GHRH and its mRNA have been reported in human placenta (11) , and GHRH mRNA was also localized to the cytrophoblast in mouse and rat placenta by in situ hybridization (12, 13) . Somatostatin, the GH-inhibiting hormone, has been found in human placenta (14) by immunohistochemical studies revealing its localization in the cytotrophoblast and in the stroma of placental villi. Notably, its pattern of expression resembles the one reported here for ghrelin, decreasing at the end of gestation (15) . Moreover, the new discovered hormone leptin was found in human placentae and its localization was consistently observed in the cytoplasm of syncytiotrophoblast cells (16) . Finally, IGF-1 is expressed primarily in syncytiotrophoblast, whereas IGF-2 mRNA appears in placental cytotrophoblast localized in the superficial basal plate (17, 18) . IGF-1 mRNA levels are highest at first trimester, slightly decreased by second trimester and lowest at term. IGF-2 reach a peak of expression in the second trimester, while lower levels are observed in the first trimester and normal term (19, 20) . The presence of ghrelin in placenta here reported suggests its involvement in a model of fetalmaternal interaction throughout paracrine, autocrine as well as endocrine communication.
To date, several possible functional involvements of ghrelin could be assigned during intrauterine development, such as the local modulation of GH release and/or the influence on maternal and/or fetal pituitary GH secretion. The physiological relevance of this finding is yet unclear but several possibilities can be pointed forward (21) . Placentaderived ghrelin could influence fetal growth and maturation. In support of this, it has been shown that exogenous GH administration increase placental and fetal growth, whereas GH deficiency is associated with fetal growth retardation (22) . Whether alteration in ghrelin-gene expression could lead to growth deficiency and/or intrauterine growth retardation needs to be established. Interestingly, the ghrelin receptor is closely located to the map position of the Brachmann-de-Lange Syndrome, a pre and postnatal growth deficiency (23) . Finally, ghrelin could act by regulating the fetal hypothalamus-pituitary-adrenal axis, since it has been shown that GHS administration to adult rodents and human leads to increased circulating level of ACTH and cortisol (24) , although whether this also happen in the fetal period is yet unknown. In any case, the finding that ghrelin in placenta shows a period of pregnancy-related expression, a fact not paralleled in gastric tissue, suggest how more than a tissue reporter, ghrelin may have physiological functions in gestation.
In conclusion, the stomach-derived somatotroph-controlling hormone ghrelin is expressed in both human and rat placental tissues, with a peculiar cellular pattern of distribution. Ghrelin expression rises at mid pregnancy decreasing thereafter, a fact suggesting a physiological regulatory role. 
